Brief: Design Therapeutics Posts Quarterly Loss Per Share Of 31 Cents
10/05/2021 22:28
May 10 (Reuters) - Design Therapeutics Inc DSGN.O :
* DESIGN THERAPEUTICS ANNOUNCES BUSINESS HIGHLIGHTS
AND REPORTS
FIRST QUARTER 2021 FINANCIAL RESULTS
* DESIGN THERAPEUTICS INC - ON-TRACK TO INITIATE PHASE 1
CLINICAL
TRIAL FOR TREATMENT OF FRIEDREICH ATAXIA IN FIRST HALF OF 2022
* DESIGN THERAPEUTICS INC QTRLY LOSS PER SHARE 31 CENTS
Source text for Eikon: ID:nGNX5DLhCh
Further company coverage: DSGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1